PFEPfizer Inc.
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- $0.87Beat
- vs $0.72 expected on Nov 3
- Stock move on it
- −2.18%
- one session
- Typical move
- ±1.8%
- average over 2 reports
- Price
- $28.83
- −2.11% today · $143B cap
Past and upcoming reports
2
| Nov 3, 2026 | Sep 30, 2026 | Time not given | $0.72 | Beat$0.87 | −2.18% |
| Jul 29, 2026 | Jun 30, 2026 | Time not given | $0.68 | not recorded | −1.35%2d |
After the report
Jul 29, 2026 report
This covers the Jul 29, 2026 report. The Nov 3, 2026 numbers are in the table above.
Pfizer Q2 Earnings: Stock Slips 0.95% as Growth Concerns Persist
Pfizer's Q2 2026 earnings report on July 29 led to a 0.95% decline in shares, as the market focused on weak growth trends and a cautious outlook. While actual EPS was not confirmed, consensus stood at $0.68. The company highlighted pipeline advances, but revenue growth remains sluggish at 1.4% TTM, and EPS is forecast to decline over the next five years. The stock now trades below its 50- and 200-day moving averages, reflecting persistent growth concerns.
Reported against expected
Actual EPS not confirmed. consensus estimate was $0.68. The stock declined 0.95% post-report, suggesting the market viewed results as lackluster.
Guidance
Forward guidance implied by weak EPS growth forecasts (-9.1% 5Y CAGR) and negative EPS next year growth (-3.68%) indicates continued revenue headwinds from COVID product declines and pipeline transition.
How the stock reacted
PFE fell 0.95% to $24.91 on July 30 with volume of 37.1M shares, above the recent average, as investors reacted to the earnings release.
What changed
Q2 report confirmed weak revenue growth. stock declined 0.95%.
What the price now assumes
Market prices prolonged revenue trough. PFE trades below both 50- and 200-day SMAs.
What it means for the business
Maintain Hold bias pending pipeline-driven revenue inflection evidence in 2027.
The next one to three months, as we saw it then
Better case20%
Pipeline success (LITFULO, other) drives revenue growth re-acceleration, leading to multiple expansion toward analyst target of $28.5.
Base case55%
Revenue stabilizes at current levels. gradual pipeline contribution offsets COVID declines. stock trades in $24-$26 range.
Worse case25%
Continued revenue decline due to lack of new blockbusters. dividend cut risk (payout ratio 127%) materializes. stock breaks below $24 support.
If you hold it
Hold unless next-quarter revenue misses guidance materially or customer concentration risk worsens.
If you are watching
Add only if next-quarter guidance is reiterated or raised. avoid if guidance is cut or geopolitical risk escalates.
Scenario odds are a judgement, not measured.